← Eichor
Condition: Chemoradiotherapy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Chemoradiotherapy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Nedaplatin Versus Cisplatin in Treatment for Nasopharyngeal Carcinoma
Phase 3 · 1 location(s) · Affiliated Cancer Hospital & Institute of Guangzhou Medical · NCT04437329Bone Marrow Protective Effect of Trilaciclib in Postoperative CCRT for LA-HNSCC
Phase 2 · 1 location(s) · Hunan Cancer Hospital · NCT06752798HPV After chemoRadioTherapy
Phase N/A · 1 location(s) · General University Hospital, Prague · NCT07493928NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer
Phase 1 · 7 location(s) · Akamis Bio · NCT06459869Phase I Trial of CArbonic Anhydrase Inhibition in Combination With Radiochemotherapy or Radioimmunotherapy in Small Cell
Phase 1 · 2 location(s) · Centre Antoine Lacassagne · NCT03467360Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patient
Phase 2 · 153 location(s) · NRG Oncology · NCT06532279DCE-MRI Based on 4D Free Breathing for Predicting Preoperative Neoadjuvant Chemoradiotherapy for Esophageal Cancer
NA · 1 location(s) · Yunnan Cancer Hospital · NCT06755866Preoperative Radiotherapy And ASTX660 in Rectum Cancer
Phase 1 · 2 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT05912075Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy
NA · 20 location(s) · First Affiliated Hospital of Guangxi Medical University · NCT05892354Vorasidenib Maintenance for IDH Mutant Astrocytoma
Phase 3 · 33 location(s) · European Organisation for Research and Treatment of Cancer - · NCT06809322Randomized Phase III Trial Testing Maintenance Olaparib Versus Observation After Adjuvant Chemoradiation for p53abn Endo
Phase 3 · 15 location(s) · Gustave Roussy, Cancer Campus, Grand Paris · NCT06712472BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)
Phase 2 · 33 location(s) · SCRI Development Innovations, LLC · NCT06773910Efficacy and Safety of Prophylactic Cranial Irradiation Versus MRI Surveillance in Patients With Limited-stage Small Cel
Phase 3 · 2 location(s) · Shandong Cancer Hospital and Institute · NCT04829708Innovative Patient-partner-guided Virtual Group Speech Pathology Intervention Model in Head and Neck Cancer
Phase 1/Phase 2 · 1 location(s) · Centre hospitalier de l'Université de Montréal (CHUM) · NCT05621889Leucine Plus Radiochemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer
NA · 1 location(s) · Second Affiliated Hospital, School of Medicine, Zhejiang Uni · NCT07359989A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable
Phase 3 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT04951635Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Phase 2 · 1 location(s) · Roswell Park Cancer Institute · NCT06995508Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06727617Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568Chemoradiotherapy for Advanced Esophageal Cancer
Phase 2 · 1 location(s) · AHS Cancer Control Alberta · NCT02297217A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally
Phase 2/Phase 3 · 2 location(s) · Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT07454720Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Phase 3 · 1 location(s) · Chinese Academy of Medical Sciences · NCT03731442Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
Phase 2 · 12 location(s) · Sun Yat-sen University · NCT06455410Incentive Spirometry to Improve Outcomes in Lung Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Therap
NA · 1 location(s) · The Cooper Health System · NCT06688422Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invas
Phase 3 · 11 location(s) · Astellas Pharma Global Development, Inc. · NCT07566156Tiraglolumab Atezolizumab and Chemoradiotherapy in Localized Anal Carcinoma (TIRANUS)
Phase 2 · 15 location(s) · Grupo Espanol Multidisciplinario del Cancer Digestivo · NCT05661188TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT04481256TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Phase 3 · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT05188313
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.